By Scott Matusow : Written by Kyle Dennis. Investor Joseph Edelman leads Perceptive Advisors and since 1999 the fund has returned an annualized 30.2%. Last year, the fund returned about 48%. Edelman works with six biotech analysts to find companies that can be huge winners. The fund's strategy ...
The FDA grants Breakthrough Therapy Designation (BTD) to InterMune 's ( ITMN -2.4% ) pirfenidone for the treatment of idiopathic pulmonary fibrosis. Under this designation the agency expedites the development
The FDA acknowledges the receipt of Intermune 's ( ITMN ) resubmitted NDA for pirfenidone. The PDUFA date in November 23, 2014. The agency sent the company a CRL in May 2010 recommending
the value of convertible debt, certain holders of InterMune 's ( ITMN -0.6% ) Convertible Senior Notes exchange the debt ..... of $18.88 and a gain on principal of $23.1M. InterMune expects to issue all shares by July 7. 8-K Post
Wall Street Breakfast Editors submit: Economy Ukraine has gone over Gazprom's deadline to pay its $1.95B gas bill by this morning. Ukraine now faces a potential shut off to its supply, as all gas going forward must be prepaid. The two attempted to continue the EU-brokered talks yesterday evening,
By Joe McCann : Overview: Despite a significant run in the valuation of InterMune ( ITMN ) on the back of positive Phase III ASCEND data in March, I have not seen much of an attempt to put definitive numbers around
competing product on the market by 2015. InterMune decided to divest Actimmune, its only ..... and other key patents have expired. InterMune will have to rely on orphan-drug exclusivity ..... related patents to fend off competitors. InterMune 's lead drug candidate is designed to
May 19 (Reuters) - InterMune Inc shares jumped as much as 15 percent on Monday, after the biotechnology company said it would resubmit for U.S. approval its drug to treat a fatal lung disease after...
results of Phase III clinical trials for InterMune ’s Esbriet and Boehringer Ingelheim ..... our no-moat, stable trend rating for InterMune . The general view from physicians was ..... The current regulatory timeline for InterMune is to resubmit its application to the
InterMune reported first-quarter results that were better than our expectations and increased its Esbriet guidance for the year. Nevertheless